Aprea Therapeutics Inc
For the period ended Jun 20, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 20, 2024 · Filed Apr 25, 2024
Contents
COMPENSATION PROGRAM
The table below depicts our 2023 compensation program for our non-employee directors and was determined after considering input from Pay Governance.
| | | | |
|---|---|---|---|
| Compensation Elements – Non-Employee Director Compensation Program | |||
| Cash · · | |||
| Annual Cash Retainer | | $40,000 | |
| Lead Independent Director Retainer | | $20,000 | |
| Annual Committee Chair Retainer | | | |
| Audit | | $7,500 | |
| Compensation | | $5,000 | |
| Nominating and Corporate | | | |
| Governance | | $4,000 | |
| Research and Development | | $4,000 | |
| Committee Member Retainer | | | |
| Audit | | $7,500 | |
| Compensation | | $6,000 | |
| Nominating and Corporate | | | |
| Governance | | $4,000 | |
| Research and Development | | $4,000 | |
| Equity | | | |
| Initial Equity Grant | | $ | 185,000 (targeted value) in stock options vesting in three equal annual installments |
| Annual Equity Retainer | | $ | 150,000 (targeted value) in stock options (80%) and RSUs (20%), each vesting on the first anniversary of the date of grant and granted following the annual meeting of stockholders. The Compensation Committee, in consultation with Pay Governance, makes a determination on the target dollar value for the annual equity retainer for directors for each fiscal year, but the target dollar value will not exceed $150,000. |
| Given the trading price of our common stock, in consultation with Pay Governance, we made a determination to calibrate the annual equity retainer for 2023 in the context of market, executive grant positioning and aggregate share usage constraints. Thus, for 2023 we did not award the full targeted value of the annual equity retainer. The approximate value of the annual equity retainer for 2023 was $7,225. | |||
Our non-employee directors are also reimbursed for their business-related expenses incurred in connection with attendance at Board and Committee meetings and related activities. Our only employee director, Dr. Gilad, received no separate compensation for his service on the Board. Please see the 2023 Summary Compensation Table for a summary of the compensation received by Dr. Gilad as our President and Chief Executive Officer in 2023.
| | 29 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.